# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Geronimo (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI016-SYN
- Date: 2026-10-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Roberta Whitehorse-Lindgren, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Sixteen-week review after twelve sessions of therapy. **S**

## History of present illness

Geronimo returns sixteen weeks after intake, with the interpreter. He finished the twelfth session of cognitive processing therapy last week. Nightmares now come about once every two weeks, and he sleeps six hours most nights. He had one evening of heavy drinking three weeks ago, which he raised himself; since then he has had a single drink on a few evenings. He takes sertraline 50 mg, naltrexone and thiamine without side effects and has not fallen. His stool test was negative and the hepatitis C and B tests show no infection and no immunity to hepatitis B. He says he prays in his own way and that this is part of how he is doing; he did not describe it and was not asked. He wants his zoster and Tdap vaccines today. **S**

| Element | Detail |
|---|---|
| Therapy | Twelve of twelve sessions completed |
| PCL-5 | 24, from 56 |
| PHQ-9 | 4 |
| AUDIT | 5, from 19 |
| PEth | 14 ng/mL |
| Screening results | Stool test and hepatitis C negative; not infected with or immune to hepatitis B |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Psychiatric | Positive | Nightmares about once every two weeks; mood steady; no thoughts of suicide |
| Gastrointestinal | Negative | No nausea or abdominal pain |
| Neurological | Negative | No dizziness or falls |

3 systems reviewed. **S**

## Current medications

- Thiamine 100 mg oral tablet, one tablet daily **S**
- Naltrexone 50 mg oral tablet, one tablet daily; carries a wallet card saying that naltrexone blocks opioid pain medicines **S**
- Sertraline 50 mg oral tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/76 mmHg; pulse 70 bpm; respirations 16/min; temperature 36.5 °C; oxygen saturation 97% on room air; weight 67.6 kg; BMI 22.6 kg/m². All vital signs are synthetic.

PCL-5: 24; PHQ-9: 4; AUDIT: 5; AST: 29 U/L; ALT: 25 U/L; GGT: 48 U/L; PEth (alcohol marker): 14 ng/mL. All results are synthetic.

## Change since baseline

- PCL-5: 56 at baseline, 24 at this visit **S**
- PHQ-9: 11 at baseline, 4 at this visit **S**
- AUDIT: 19 at baseline, 5 at this visit **S**
- AST: 58 U/L (high) at baseline, 29 U/L at this visit **S**
- ALT: 36 U/L at baseline, 25 U/L at this visit **S**
- GGT: 112 U/L (high) at baseline, 48 U/L at this visit **S**
- PEth (alcohol marker): 236 ng/mL (high) at baseline, 14 ng/mL at this visit **S**

## Immunizations given today

- Tdap vaccine; no booster he can recall **S**
- Recombinant zoster vaccine, first of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/76 seated and 126/74 standing; pulse 70; weight 67.6 kg, BMI 22.6 |
| Mental status | Relaxed and humorous; full range of affect; no thoughts of suicide or of harming anyone |
| Gait | Steady; Timed Up and Go 11 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Post-traumatic stress disorder, chronic** (F43.12). PCL-5 24, from 56: a large and meaningful response to cognitive processing therapy and sertraline; he no longer meets the symptom threshold on the checklist, though the diagnosis stays on his list while treatment continues. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Continue sertraline 50 mg for at least six to twelve months, then review.
   - Booster therapy sessions monthly for three months.
   - PCL-5 in three months.
2. **Alcohol use disorder, moderate** (F10.20). AUDIT 5 and PEth 14 ng/mL; liver tests normal. One heavy evening in sixteen weeks, met without blame. **S**
   - Continue naltrexone for at least three to six more months, then review with him.
   - Continue thiamine while he is drinking at all.
3. **History of falling** (Z91.81). No falls in sixteen weeks; Timed Up and Go 11 seconds. **S**
   - Continue the exercise program.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PTSD symptom severity (PCL-5) | Baseline, then every visit during treatment | Completed today | 24, from 56 |
| Self-management | Trauma-focused psychotherapy (cognitive processing therapy), sessions attended | Weekly for twelve sessions | Completed today | Twelve of twelve sessions completed; monthly boosters planned |
| Survey | Depressive symptoms (PHQ-9) | Baseline, then monthly during active treatment | Completed today | 4, from 11; item 9 scored 0 |
| Survey | Suicide-risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; 988 card carried |
| Self-management | Drinking since the last visit, against his own goal | Every visit | Completed today | One heavy evening three weeks ago; otherwise a single drink on a few evenings; AUDIT 5 |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | Before starting, at four to six weeks, then every three to six months | Completed today | AST 29, ALT 25, GGT 48 U/L: normal |
| Laboratory | PEth, a blood marker of drinking over the past two to four weeks | At baseline and every one to three months during treatment, with consent | Completed today | 14 ng/mL, from 41 |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | Every visit | Completed today | No opioid use; no side effects |
| Medication safety | SSRI safety: sodium, bleeding, falls and side effects | Sodium within the first month in older adults; review at each dose change | Up to date | Sodium 137 mmol/L five weeks ago; no bleeding, dizziness or falls on 50 mg |
| Medication safety | Prazosin for nightmares | When nightmares persist despite first-line treatment | Not indicated | Nightmares about once every two weeks; not needed |
| Examination | Falls and gait (Timed Up and Go), orthostatic blood pressure | At intake and every visit after a fall | Completed today | Timed Up and Go 11 seconds; no orthostatic drop; no falls |
| Self-management | Traditional healing alongside clinic care, at his choice | Every visit | Completed today | His own prayer and ways continue, as he chooses; nothing asked |

## Goal progress

- Sleep most nights with nightmares no more than once a week. Outcome by 2026-10-28: Nightmares from most nights to about once every two weeks; sleeping six hours most nights. **S**
- Lower PTSD symptoms by a meaningful amount (PCL-5 down at least 10 to 20 points). Outcome by 2026-10-28: PCL-5 56 to 24 after twelve sessions of cognitive processing therapy. **S**
- Drink no more than one drink on any day, and no drinking before riding. Outcome by 2026-10-28: AUDIT 19 to 5; PEth 236 to 14 ng/mL; one evening of heavy drinking in sixteen weeks. **S**
- No further falls. Outcome by 2026-10-28: No falls in sixteen weeks; Timed Up and Go 13 to 11 seconds. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023), United States Department of Veterans Affairs and Department of Defense (synopsis: Ann Intern Med 2024;177(3):363-374)
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults (2017), American Psychological Association
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Special General Memorandum 94-08: Statement of Policy for the Traditional Cultural Advocacy Program (1994), Indian Health Service
- Falls Prevention in Community-Dwelling Older Adults: Interventions (2024), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Tdap and the first recombinant zoster dose given today; second zoster dose in two to six months. Hepatitis B vaccination offered and to be decided at the next visit. Review in three months with the PCL-5. Booster therapy sessions monthly. Call the clinic or 988 at any hour. **S**

